Эритропоэтины в онкологии: показания к применению и проблемы

1. Albain K, Crowley J, LeBlanc M. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618–26.
2. Wagner W, Hermann R, Hartlapp J. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenthaer Onkol 2000; 176: 73–80.
3. Ludwig H, Van Belle S, Barrett-Lee et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293–306.
4. Scrijvers D, Roila F and on behalf of the ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use. Ann Oncol 2009; 20(Suppl 4): iv159–iv161; doi:10.1093/annonc/mdp161.
5. Henry D, Abels R. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol. 1994; 21(suppl 3): 21–8.
6. Demetri G, Kris M, Wade J et al. Quality-of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study—Procrit Study Group.  J Clin Oncol 1998; 16: 3412–25.
7. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem. Semin Hematol 1997; 34: 20–6.
8. Gabrilove J, Cleeland C, Livingston R et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to threetimes- weekly dosing. J Clin Oncol 2001; 19: 2875–82.
9. Littlewood T, Bajetta E, Nortier J et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865–74.
10. Vansteenkiste J, Pirker R, Massuti B et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211- 1220, 2002
11. Osterborg A, Brandberg Y, Molostova V et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486–94.
12. Taylor K, Ganly P, Charu V et al. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. Blood 2005; 106: abstr 3556.
13. Grote T, Yeilding A, Castillo R et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: A randomized, double-blind, placebo-controlled trial.  J Clin Oncol 2005; 23: 9377–86.
14. Witzig T, Silberstein P, Loprinzi C et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.  J Clin Oncol 2005; 23: 2606–617.
15. Kotasek D, Steger G, Faught W et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: Results of a double-blind, placebocontrolled, randomised study. Eur J Cancer 2003; 39: 2026–34.
16. Moebus V, Lueck H, Thomssen C et al. The impact of epoetin-alpha on anemia, red blood cell RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 2007; 25 (suppl); abstr 569.
17. Pirker R, Ramlau R, Schuette W et al. A phase 3 randomized, double blind, placebocontrolled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa. J Thorac Oncol 2007; 2: abstr PD6-3-6.
18. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708–14.
19. Seidenfeld J, Pipe M, J et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment: Comparative Effectiveness Review no. 3. Prepared by Blue Cross and Blue Shield Association Evaluation Center Evidence-based Practice Center under contract no. 290-02-0026. Rockville, MD, Agency for Healthcare Research and Quality, 2006. www.effectivehealthcare.arhq.gov/reports/final.cfm
20. Ross S, Allen I, Henry D et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther 2006; 28: 801–31.
21. Aapro M, Coiffier B, Dunst J et al. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br J Cancer 2006; 95: 1467–73.
22. Smith R Jr, Aapro M, Ludwig H et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebocontrolled study.  J Clin Oncol 2008; 26: 1040–50.
23. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255–60.
24. Leyland-Jones B, Semiglazov V, Pawlicki M et al Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study.  J Clin Oncol 2005; 23: 5960–72.
25. Wright J, Ung Y, Julian J et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.  J Clin Oncol 2007; 25: 1027–32.
26. Overgaard J, Hoff C, Sand Hansen H et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group (DAHANCA 10) randomized trial. Presented at 14th European Cancer Conference, Barcelona, Spain, September 23–27, 2007: abstr 6LB.
27. Hedenus M,  Adriansson M, San Miguel J et al: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394–03.
28. Amgen: Update to Hedenus et al (2003), Safety of Erythropoiesis-Stimulating Agents (ESAs) in Oncology: Background Information for Oncologic Drugs Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-01-01-Amgen.pdf
29. Thomas G, Ali S, Hoebers FJ, et al. Phase trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008; 108: 317–25.
30. Amgen: Amgen announces interim results Aranesp “PREPARE” study in breast cancer patients [Amgen press release]: November 30, 2007. 
Http:// wwwext.amgen.com/ media / media_pr_detail . jsp? year_2007 & releaseID_ 1083091
31. Azria D, Zouhair A, Serre A et al. Anemia head and neck cancers. Bull Cancer 2005; 92: 445–51.
32. Bennett C, Silver S, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancerassociated anemia. JAMA 2008; 299: 914–24.
33. Henke M, Mattern D, Pepe M et al. Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings? J Clin Oncol 2006; 24: 4708–13.
34. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 2009; 373: 1532–42.
35. Tonelli M, Reiman T, Reaume M et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180(11).
36. Gascon P. Safety Update on Erythropoiesis-Stimulating Agents:Trials Within and Outside the Accepted Indications. Oncologist 2008; 13(suppl 3): 4–10.
37. Nowrousian M, Dunst J, Vaupel P. Erythropoiesis-Stimulating Agents: Favorable Safety Profile When Used as Indicated. Strahlenther Onkol 2008; 184: 121–36.
38. Melosky B. Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol 2008; 15(Suppl 1): S10–5.
39. Ludwig H, Crawford J, Cterborg F et al. Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia. J Clin Oncol 2009; 27: s1–10.
40. Heit J, Silverstein M, Mohr D et al: Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000; 160: 809–15.
41. Blom J, Doggen C, Osanto S et al: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–22.
42. Lyman G, Glaspy J.  Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 2006; 106: 223–3.

Н.С.Бесова

Отделение химиотерапии РОНЦ им. Н.Н.Блохина РАМН, Москва